勝華新材(603026.SH):擬投資1億元、同時成立青島研究院作為研發平台
格隆匯11月15日丨勝華新材(603026.SH)公佈,公司擬與中國石油大學(華東)(以下簡稱:“甲方”)簽訂《共建石大勝華先進能源材料研究院的協議》《研發合作協議》(合併簡稱“協議”)。
為增強公司綜合研發實力,增加公司前沿技術儲備,提升公司市場競爭力,公司擬投資1億元,同時在青島市西海岸新區註冊成立勝華研究院(青島)有限公司(暫定名,最終以工商登記註冊為準)(“青島研究院”)作為乙方研發平台,對接甲方的科研機構石大勝華先進能源材料研究院。
青島研究院研發金額約1億元,其中科研項目研發費、高端人才引進經費合計約5000萬元,科研設備購置費約5000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.